Fennec Pharmaceuticals Net Worth
Fennec Pharmaceuticals Net Worth Breakdown | FENC |
Fennec Pharmaceuticals Net Worth Analysis
Fennec Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Fennec Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Fennec Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Fennec Pharmaceuticals' net worth analysis. One common approach is to calculate Fennec Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Fennec Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Fennec Pharmaceuticals' net worth. This approach calculates the present value of Fennec Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Fennec Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Fennec Pharmaceuticals' net worth. This involves comparing Fennec Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Fennec Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Fennec Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Fennec Pharmaceuticals' net worth research are outlined below:
| Fennec Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 21.25 M. Net Loss for the year was (16.05 M) with profit before overhead, payroll, taxes, and interest of 46.15 M. | |
| Fennec Pharmaceuticals currently holds about 14.91 M in cash with (17.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.57. | |
| Fennec Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 400000 shares by Hackman Jeffrey S. of Fennec Pharmaceuticals at 5.58 subject to Rule 16b-3 |
Fennec Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Fennec Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Fennec Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Fennec Pharmaceuticals Target Price Consensus
Fennec target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Fennec Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 5 | Strong Buy |
Most Fennec analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Fennec stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Fennec Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationFennec Pharmaceuticals Target Price Projection
Fennec Pharmaceuticals' current and average target prices are 6.75 and 13.60, respectively. The current price of Fennec Pharmaceuticals is the price at which Fennec Pharmaceuticals is currently trading. On the other hand, Fennec Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Fennec Pharmaceuticals Market Quote on 27th of February 2025
Target Price
Analyst Consensus On Fennec Pharmaceuticals Target Price
Know Fennec Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Fennec Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Fennec Pharmaceuticals backward and forwards among themselves. Fennec Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Fennec Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Gendell Jeffrey L | 2024-12-31 | 199.3 K | Lion Point Capital, Lp | 2024-12-31 | 195.7 K | Northern Trust Corp | 2024-12-31 | 136.8 K | Goldman Sachs Group Inc | 2024-12-31 | 71.2 K | Charles Schwab Investment Management Inc | 2024-12-31 | 61.1 K | Bank Of New York Mellon Corp | 2024-12-31 | 52.1 K | Hartford Financial Management Inc. | 2024-12-31 | 49.8 K | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 44.6 K | Clayton Partners, Llc | 2024-12-31 | 40.5 K | Southpoint Capital Advisors Lp | 2024-12-31 | 4.1 M | Sonic Gp Llc | 2024-12-31 | 2.4 M |
Follow Fennec Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 184.34 M.Market Cap |
|
Project Fennec Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.54) | (0.56) | |
| Return On Capital Employed | (0.60) | (0.57) | |
| Return On Assets | (0.54) | (0.56) | |
| Return On Equity | 1.24 | 1.30 |
When accessing Fennec Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Fennec Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Fennec Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Fennec Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Fennec Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Fennec Pharmaceuticals' management manipulating its earnings.
Evaluate Fennec Pharmaceuticals' management efficiency
Fennec Pharmaceuticals has return on total asset (ROA) of 0.027 % which means that it generated a profit of $0.027 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.0559) %, meaning that it created substantial loss on money invested by shareholders. Fennec Pharmaceuticals' management efficiency ratios could be used to measure how well Fennec Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 1.30, whereas Return On Tangible Assets are forecasted to decline to (0.56). At present, Fennec Pharmaceuticals' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 1.09, whereas Total Assets are forecasted to decline to about 16.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.50) | (0.48) | |
| Tangible Book Value Per Share | (0.50) | (0.48) | |
| Enterprise Value Over EBITDA | (29.38) | (27.91) | |
| Price Book Value Ratio | (29.50) | (28.03) | |
| Enterprise Value Multiple | (29.38) | (27.91) | |
| Price Fair Value | (29.50) | (28.03) | |
| Enterprise Value | 113.1 M | 121.1 M |
Leadership effectiveness at Fennec Pharmaceuticals is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 3.532 | Revenue | Quarterly Revenue Growth 0.07 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fennec Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fennec Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fennec Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Fennec Pharmaceuticals Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
8K | 7th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 5th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Fennec Pharmaceuticals Earnings Estimation Breakdown
The calculation of Fennec Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Fennec Pharmaceuticals is estimated to be -0.021675 with the future projection ranging from a low of -0.035 to a high of -0.0075. Please be aware that this consensus of annual earnings estimates for Fennec Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.04 Lowest | Expected EPS | -0.0075 Highest |
Fennec Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Fennec Pharmaceuticals' value are higher than the current market price of the Fennec Pharmaceuticals stock. In this case, investors may conclude that Fennec Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Fennec Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 5 | 39.66% | -0.21 | -0.021675 | -0.04 |
Fennec Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Fennec Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Fennec Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Fennec Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Fennec Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Fennec Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Fennec Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Fennec Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Fennec Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-04 | 2024-09-30 | -0.09 | -0.21 | -0.12 | 133 | ||
2024-08-13 | 2024-06-30 | -0.03 | -0.2 | -0.17 | 566 | ||
2024-05-14 | 2024-03-31 | 0.26 | 0.47 | 0.21 | 80 | ||
2024-03-21 | 2023-12-31 | -0.02 | -0.1 | -0.08 | 400 | ||
2023-11-06 | 2023-09-30 | -0.12 | -0.07 | 0.05 | 41 | ||
2023-08-03 | 2023-06-30 | -0.16 | -0.21 | -0.05 | 31 | ||
2023-05-11 | 2023-03-31 | -0.21 | -0.23 | -0.02 | 9 | ||
2023-03-29 | 2022-12-31 | -0.26 | -0.26 | 0.0 | 0 | ||
2022-11-11 | 2022-09-30 | -0.18 | -0.31 | -0.13 | 72 | ||
2022-08-12 | 2022-06-30 | -0.14 | -0.19 | -0.05 | 35 | ||
2022-05-12 | 2022-03-31 | -0.14 | -0.14 | 0.0 | 0 | ||
2022-02-28 | 2021-12-31 | 0.75 | -0.18 | -0.93 | 124 | ||
2021-11-10 | 2021-09-30 | -0.17 | -0.16 | 0.01 | 5 | ||
2021-08-10 | 2021-06-30 | -0.19 | -0.15 | 0.04 | 21 | ||
2021-05-13 | 2021-03-31 | -0.13 | -0.18 | -0.05 | 38 | ||
2021-03-30 | 2020-12-31 | -0.19 | -0.13 | 0.06 | 31 | ||
2020-11-16 | 2020-09-30 | -0.19 | -0.24 | -0.05 | 26 | ||
2020-08-05 | 2020-06-30 | -0.18 | -0.21 | -0.03 | 16 | ||
2020-05-14 | 2020-03-31 | -0.19 | -0.19 | 0.0 | 0 | ||
2020-02-14 | 2019-12-31 | -0.13 | -0.18 | -0.05 | 38 | ||
2019-11-12 | 2019-09-30 | -0.2 | -0.09 | 0.11 | 55 | ||
2019-08-09 | 2019-06-30 | -0.14 | -0.24 | -0.1 | 71 | ||
2019-05-09 | 2019-03-31 | -0.15 | -0.13 | 0.02 | 13 | ||
2019-03-13 | 2018-12-31 | -0.14 | -0.15 | -0.01 | 7 | ||
2018-11-13 | 2018-09-30 | -0.14 | -0.14 | 0.0 | 0 | ||
2018-08-13 | 2018-06-30 | -0.11 | -0.14 | -0.03 | 27 | ||
2018-05-14 | 2018-03-31 | -0.12 | -0.09 | 0.03 | 25 | ||
2018-03-28 | 2017-12-31 | -0.14 | -0.14 | 0.0 | 0 | ||
2017-08-11 | 2017-06-30 | -0.05 | -0.11 | -0.06 | 120 | ||
2005-11-07 | 2005-09-30 | -6.48 | -5.94 | 0.54 | 8 |
Fennec Pharmaceuticals Corporate Management
| Mark Meier | VP Commercial | Profile | |
| Christiana MBA | Chief Officer | Profile | |
| Mark Gowland | Controller | Profile | |
| Terry Evans | Chief Officer | Profile | |
| Robert Andrade | Chief Officer | Profile | |
| Dr MS | Chief Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fennec Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Fennec Stock refer to our How to Trade Fennec Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fennec Pharmaceuticals. If investors know Fennec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fennec Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.04) | Revenue Per Share | Quarterly Revenue Growth 0.07 | Return On Assets | Return On Equity |
The market value of Fennec Pharmaceuticals is measured differently than its book value, which is the value of Fennec that is recorded on the company's balance sheet. Investors also form their own opinion of Fennec Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Fennec Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fennec Pharmaceuticals' market value can be influenced by many factors that don't directly affect Fennec Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fennec Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fennec Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fennec Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.